US biotech licenses antibody from Takeda for new kidney drugs

Goldfinch Bio, a US company focused on developing treatments for kidney disease, has agreed to license a cannabinoid receptor 1 (CB1) antibody from Japanese pharmaceutical manufacturer Takeda.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

BioNTech fires shots at Moderna's next-generation vaccine

20 February 2026 The German biotech claims the newly approved vaccine infringes its mRNA patent, deepening an already complex feud with billions of dollars at stake.

Americas

Abbott unit defends European protection for heart valve ‘cuff’ design

19 February 2026 An EPO appeals board has denied Boston Scientific’s bid to revoke St Jude Medical’s transcatheter aortic valve replacement (TAVR) patent, but declined to hand a complete victory to the patent owner.

Americas

Natera targets ex-employee over mass file download before rival move

19 February 2026 The genetic testing firm claims that a former oncology specialist stole hundreds of confidential files in the dead of night, days before moving to a competitor.

More features

BioNTech fires shots at Moderna's next-generation vaccine

Mintz gains ex-Winston & Strawn partner and ITC expert

Abbott unit defends European protection for heart valve ‘cuff’ design

Natera targets ex-employee over mass file download before rival move

Hogan Lovells makes senior public and administrative hire in Italy

Danaher moves to acquire Masimo in $9.9bn deal

Generic rival blocked as AZ defends diabetes stronghold

Emotional Perception exclusive: ‘We are now very much open for business’

US biotech licenses antibody from Takeda for new kidney drugs

More on this story

Editor's picks

Editor's picks

More features